LATEST NEWS
04.30.2012
San Diego: CalAsia Pharmaceuticals appointed Dr. Eyitayo "Tayo" Fakunle as head of translational research.
View Full Article
HOME
CalAsia's Mission: CalAsia's mission is to accelerate seminal academic discoveries into safe and effective treatments for both unmet and under-served medical needs.
CalAsia's Drug-discovery: CalAsia Pharmaceuticals, Inc. is a privately held early stage pharmaceutical company focused on the rapid discovery of drug-like small molecules by utilizing its core technologies. In detail, CalAsia core technologies combine functional fragment screening with X-ray crystallography co-crystallization to rationally design and synthesize New Chemical Entities (NCEs) with drug-like properties. By differential fragment screening of closely related isotypes, CalAsia develops selective NCEs early in the drug discovery process thereby increasing the quality of potential drug candidates. In addition, CalAsia employs stem-cell technology to evaluate its lead drug candidates for proof of concept in disease derived human induced pluripotent stem cells (iPSC), thereby rapidly transitioning our drug discovery programs into preclinical and clinical development studies. Currently, CalAsia has several drug-discovery programs for the treatment unmet medical needs for CNS, metabolic, inflammation, oncology and infectious diseases. Of note, the CalAsia team has decades of drug-discovery experience and has been involved in numerous drug-discovery programs that have resulted in multiple clinical candidates as well as one marketed drug.
CalAsia's Services: The CalAsia team provides its expertise; which includes cloning, recombinant protein expression (E. coli, Baculovirus & Yeast), recombinant protein purification, biochemical assays, cellular assays, fragment screening, and X-ray crystallography co-crystallization; to the drug-discovery community through contract research.